Live feed16:01:00·1262dPRReleasevia QuantisnowDeciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 OnlyByQuantisnow·Wall Street's wire, on your screen.DCPH· Deciphera Pharmaceuticals Inc.Health Care
